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Summary The relationship between poor oral health and systemic diseases has been increas-
ingly recognized over the past two decades. Atherosclerosis is an important basal component of
atherosclerotic cardiovascular disease (ACVD), which is the primary cause of death worldwide,
including Japan.
The accumulation of multiple individual epidemiological studies has paved the way for
subsequent systematic reviews that have demonstrated that periodontitis can be considered
as an emerging risk factor for ACVD. Although the causal mechanisms by which periodontitis
accelerates ACVD have not been fully elucidated, plausible evidence regarding the inflammatory
response due to inflammatory mediators and bacterial etiologies, and the recognition of altered
lipid metabolism in patients with periodontitis suggest that infection with periodontopathic
bacteria can influence atherogenesis in vitro and in vivo. Animal model studies have strengthened
this evidence. However, there have been a lack of interventional studies that show the effects of
periodontal treatment on the future risk of ACVD; this lack of evidence critically weakens the
importance of the relationship between the two diseases. This review presents a summary of the
current evidence and biological plausibility that link periodontitis to ACVD.
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56 K. Tabeta et al.1. Introduction
Periodontitis is caused by infection with a group of bacteria,
primarily Gram negative and anaerobic species. The inflam-
mation triggered by a bacterial infection is characterized by
mononuclear cell infiltration into the gingival tissues, leading
to connective tissue destruction and alveolar bone resorp-
tion. The loss of tooth function caused by periodontal
destruction diminishes masticatory function and impairs
facial configuration. Furthermore, periodontitis is a major
public health issue because it can be a source of social
inequality, decreases quality of life, and increases dental
costs; it also has a potential impact on systemic diseases.
Individual epidemiological studies and subsequent sys-
tematic reviews have demonstrated that periodontitis can
be considered as an emerging risk factor for atherosclerotic
vascular disease (ACVD) [1]. Although the causal mechan-
isms by which periodontitis accelerates ACVD have not been
fully elucidated, plausible evidence regarding the inflam-
matory response due to inflammatory mediators and bacter-
ial etiologies, and the recognition of altered lipid
metabolism in patients with periodontitis suggest that infec-
tion with periodontopathic bacteria can influence athero-
genesis (Fig. 1). Several studies conducted in vitro and using
animal models have demonstrated some causal mechanisms
in human patients with periodontitis; these mechanisms
suggest that infection and the subsequent inflammatory
response may be a key to elucidating the association
between atherosclerosis and periodontitis. This review pre-
sents a summary of recent studies on the relationship
between periodontitis and ACVD.
2. Epidemiological evidence
The association between poor oral health and ACVD has been
increasingly recognized over the past two decades. A sig-
nificant number of groups have conducted epidemiological
studies, and the findings have been systematically reviewed
several times [1—6]. A comprehensive review by an American
Heart Association (AHA) working group concluded that per-
iodontal disease is associated with atherosclerotic vasculardisease independent of known confounders [7,8]. However,
the working group further concluded that there was no
evidence of a causal link. This review further pointed out
gaps in the published research and methodological issues that
should be improved in future research, such as the need for
uniform criteria for the evaluation and case definitions of
periodontitis. It further emphasized the need for well-
designed, controlled interventional studies with standard
treatment protocols as well as considerations for issues such
as sustainability of treatment response over time [7,8]. To
this point, Dietrich et al. [9] systematically reviewed cohort
and case—control studies while minimizing the effects of
misclassification by including studies that evaluated period-
ontal probing depth/clinical attachment loss and/or radio-
graphically assessed alveolar bone loss. The researchers
observed that the association was stronger in younger adults
and that there was no evidence for an association between
periodontitis and the incidence of coronary heart disease
(CHD) in subjects aged >65 years. The conclusions from this
review were that the evidence for an increased risk of ACVD
in patients with periodontitis compared with that in patients
without the disease only applied to a limited section of the
population [9]. Thus, the clinical parameters of periodonti-
tis, such as periodontal probing depth, clinical attachment
loss, and/or radiographic assessment of bone loss, have all
been associated with an increased risk of ACVD independent
of established risk factors. However, the amount of excess
risk adjusted for ACVD risk factors varied across studies
according to the type of cardiovascular outcome and age
and sex of the subjects. Specifically, the risk has been greater
in males and younger individuals [9—12].
3. Biological plausibility
3.1. Inflammatory mediators
Atherosclerosis, an inflammatory disease, is the major cause
of ACVD and is initiated by injury to the vascular endothelium
[13—16]. It is a major cause of diseases that involve plaque
formation, plaque disruption, and subsequent atherothrom-
bosis [14,17]. Although the accumulation of atheromatous
Figure 1 Biological plausibility of the relationship between the development of atherothrombotic lesions and periodontal infection.
Bacteria entering the circulation as a result of periodontal infection, dental procedures, and routine tooth care result in varying levels
of bacteremia. This may enhance the progression of atherosclerotic cardiovascular disease (red arrow). Inflammatory mediators
produced in infected gingival tissues or as part of the hepatic response to periodontal infection may enhance the progression of
atherosclerotic cardiovascular disease (blue arrow). Dyslipidemia modulated by periodontal infection primarily affecting the hepatic
response may enhance the progression of atherosclerotic cardiovascular disease (green arrow). (For interpretation of the references to
color in this figure legend, the reader is referred to the web version of this article.)
Evidence of linking periodontitis to cardiovascular disease 57plaques in the artery wall is characteristic of atherosclerosis,
the nature of the inflammatory response in the artery wall
may be modulated by chronic infectious diseases that
directly supply pathogens into the blood stream or indirectly
influence systemic inflammation [18]. Endothelial dysfunc-
tion, the earliest indicator of cardiovascular disease, may be
modulated through a state of systemic inflammation that can
be evaluated by measuring different factors such as acute
phase protein (CRP), tumor necrosis factor-a (TNF-a), and
interleukin-6 (IL-6), which have also been reported to be
elevated in patients with periodontitis [19—21].
High-sensitivity CRP (hsCRP) has been identified to be a key
marker of atherosclerosis, and elevated levels constitute a risk
factor for ACVD [22—25]. The mechanisms of CRP production in
periodontitis patients have not been clearly demonstrated.
CRP is produced mainly in the liver in response to IL-6, but
extrahepatic production has also been confirmed at sites such
as in the endothelium of atherosclerotic plaques, smooth
muscle cells, infiltrated macrophages, and inflamed gingival
tissues [26—28]. Serum hsCRP levels are much higher among
Western individuals than among Japanese individuals.
Whereas an hsCRP level of >2 mg/L represents a high risk of
CHD development among Western populations, 1 mg/L is the
critical level among the Japanese [29]. Nakajima et al. found
that the number of patients with serum hsCRP levels >1 mg/L
decreased after periodontal therapy in a Japanese population,suggesting that periodontal therapy may potentially decrease
CHD risk in this population [19].
The TNF-a concentration is reportedly higher in the serum
of patients with periodontitis than in the serum of healthy
subjects [30]. The effects of periodontal therapy on serum
TNF-a concentration in patients with periodontitis were
observed in multiple groups [31—33]. On the other hand,
other study groups failed to detect the effects of periodontal
therapy [19,34—38]. The concept of the elevation of TNF-a in
patients with periodontitis has been controversial. The fact
that the degree of elevation of TNF-a may be lesser than that
of CRP and IL-6 may decrease the statistical power for
detecting significance in studies with small patient samples.
IL-6, a proinflammatory cytokine that can trigger systemic
inflammation and hepatic CRP production, asserts its func-
tions in an autocrine manner by way of the IL-6 receptor
[26,27]. Two randomized controlled trials (RCT) reported a
decrease in serum IL-6 concentrations in patients with per-
iodontitis [39,40] and this finding was in line with those of
other studies [41,42]. However, no significant effect of per-
iodontal treatment was observed in other studies [36,43]. A
recent meta-analysis also failed to detect the effects of
periodontal therapy on decreasing serum IL-6 levels; the
authors concluded that there was moderate evidence that
did not support the effects of nonsurgical therapy on serum
IL-6 concentrations [44].
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Periodontal bacteria enter the circulation following dental
procedures such as scaling, tooth extraction, and periodontal
probing. Routine tooth care or activities such as tooth brush-
ing, flossing, chewing, and biting can also cause varying levels
of bacteremia depending on the study design [45]. Slight
levels of bacteremia, which may consistently induce low-
grade inflammation several times a day in daily life, may
potentially have an effect on atherogenicity.
Even if the bacteria do not survive long in the circulation,
the bacterial products that remain in the blood stream, such
as the outer membrane vesicles [46] and gingipains [47], may
also cause systemic and endothelial inflammatory responses;
however, the extent to which these bacterial components or
the inflammatory cytokines derived from oral infection affect
endothelial function cannot be evaluated in humans because
of technical issues. An inflammatory response triggered in
endothelial cells induces the production of inflammatory
cytokines and chemokines and the expression of adhesion
molecules on the cell surface; this is followed by the infiltra-
tion of leukocytes.
3.3. Bacterial invasion
Several groups have reported bacterial invasion of host cells
through the invasion or adhesion of Porphyromonas gingiva-
lis, Aggregatibacter actinomycetemcomitans, and Fusobac-
terium nucleatum to macrophages, vascular endothelial
cells, and gingival epithelial cells [45]. It remains unclear
whether the invasion of bacteria plays a role in human
atherogenesis. However, internalized bacteria in epithelial
cells can certainly induce the host immune response; further-
more, parts of the bacteria may flow into the blood stream,
modulating the progression of atherosclerosis. A system of
immune evasion of P. gingivalis, where the bacteria remains
in a dominant state in the host cell, has been reported by one
study group; this may cause a prolonged inflammatory
response as observed in chronic inflammation. Using comple-
ment C5 convertase-like activity, P. gingivalis synergizes with
C5a to increase cyclic adenosine monophosphate (cAMP)
concentrations, resulting in the suppression of macrophage
immune function and enhancement of pathogen survival in
vitro and in vivo [48]. P. gingivalis, through lysine gingipain,
can subvert the protective host proinflammatory response by
direct cytokine degradation [49]. Invasion may provide
access to host proteins, iron, and other nutrients by inducing
host cell lysis or apoptosis. Egress of P. gingivalis from the
endocytic recycling pathway in gingival epithelial cells helps
in prolonging infection [50]. These observations may partly
account for the persistence of periodontal inflammation and
may influence the host inflammatory response. Downregula-
tion or evasion of immune function may give bacteria the
benefit of being able to survive, as observed in inflammatory
exudates such as gingival crevicular fluid.
3.4. Periodontal bacteria in the atheromatous
tissues
Several species of oral bacteria have been identified in the
affected disease sites of ACVD patients. Genomic DNA,mainly 16S rRNA DNA, from periodontopathic bacteria and
other species were detected by polymerase chain reaction
(PCR); however, the frequency of detection of different spe-
cies varies [51—59]. Controversially, no detection of bacterial
DNA in atheromatous specimens has also been reported by
some researchers [60—62]. Multiple groups have attempted to
detect live periodontopathic bacteria in atheromatous pla-
ques. P. gingivalis and A. actinomycetemcomitans were
detected in endothelial cells derived from homogenized ather-
omatous tissue cultures through specific antibody detection
[63]. Fresh atheromatous cells cultured with macrophages
enabled the detection of P. gingivalis in culture [64]. However,
this evidence does not necessarily indicate the actual invasion
of live bacteria on site because the observation was obtained
with cell cultures. Namely, the bacteria from contaminated
blood may have invaded cultured cells in vitro; therefore,
further studies are needed to confirm these findings. Never-
theless, these reports do indicate the possible immunological
interaction between live bacteria and atheromatous plaque
cells because the invasion of P. gingivalis into human cardio-
vascular cells such as human coronary artery endothelial cells
(HCAECs), human aortic endothelial cells (HAECs), and human
microvascular endothelial cells (HMECs)-1 has been reported
in vitro [65—69].
3.5. Effect of periodontitis on lipid metabolism
Atherosclerosis is characterized by inflammatory cell infil-
tration, foam cell formation, and lipid accumulation in the
vessel wall. Infection and inflammation are associated with
marked changes in lipid and lipoprotein metabolism. Many of
the changes in lipoproteins during infection/inflammation
help in protecting the host from the harmful effects of the
stimuli. However, in patients with chronic infection, inflam-
matory diseases, diabetes, obesity, and metabolic syndrome,
these cytokine-induced changes in the structure and function
of lipoproteins can be deleterious and may contribute to the
development of atherosclerosis [70]. Therefore, it is of
interest to determine whether periodontitis has an effect
on lipid metabolism.
Severe periodontitis has been associated with a modest
decrease in the levels of high-density lipoprotein (HDL) and
low-density lipoprotein (LDL) cholesterol concentrations and
a more robust increase in plasma triglyceride concentrations
[71,72]. HDL cholesterol is an anti-atherogenic lipoprotein
[73,74], and a low HDL cholesterol concentration has been
established as an independent risk factor for CHD [75].
In contrast, no difference in HDL cholesterol concentra-
tions was observed in the 10,590 participants in an Israeli
population study, although the total cholesterol and trigly-
ceride concentrations were higher in the patients with per-
iodontitis than in the controls, as determined by the
community periodontal index of treatment needs [76,77].
Pussinen et al. demonstrated that high combined serum
antibody levels against A. actinomycetemcomitans and P.
gingivalis were significantly associated with low HDL choles-
terol concentrations [78]. Furthermore, the same research
group demonstrated that periodontitis decreased serum HDL
cholesterol concentrations by comparing them before and
after treatment [78]. Although infection and inflammation
have been associated with a decrease in serum HDL choles-
terol, the exact mechanism has not yet been established.
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Some risk factors such as age, gender, cigarette smoking, and
presence of diabetes are common to periodontitis and ACVD.
Therefore, the relationship between these two diseases has
been carefully assessed considering the effect of these con-
founders, and periodontitis has been shown to be an inde-
pendent risk factor for CHD. The influence of diseases such as
diabetes is a plausible mechanism because the disease is
exacerbated by periodontal infection, adversely affecting
glycemic control in patients with diabetes mellitus, contri-
buting to the development of diabetic complications [79],
promoting the development of atherosclerosis, and increas-
ing CHD risk.
Chronic kidney disease (CKD) has not received much atten-
tion in the context of the relationship between atherosclerotic
disease and periodontal disease. However, the relationship
between CKD and acute coronary syndromes has been well
recognized [80,81]. End-stage renal disease is strongly asso-
ciated with premature cardiovascular death and morbidity
[82]. CKD is associated with accelerated atherogenesis, and
the adverse influence of CKD has been demonstrated by the
doubled mortality rate associated with acute coronary syn-
drome [83]. The role of chronic inflammation in the etiology of
CKD was indicated by the increase in serum CRP levels [84,85].
Inflammation, oxidative stress, and dyslipidemia in advanced
CKD have all been suggested to promote atherogenesis [86].
Previous studies also suggested an association between period-
ontitis and CKD. The atherosclerosis risk (ARIC) study demon-
strated an association between CKD and periodontitis, with an
OR of 2.0 (95% confidence interval, 1.23—3.24), and an expo-
nential increase in antibodies to periodontal pathogens has
been associated with CKD [87,88]. A retrospective study from
the Third National Health and Nutrition Survey-NHANES III in
the USA demonstrated that edentulous adults are more likely
to have CKD [89]. Interventional studies in subjects with
generalized chronic periodontitis demonstrated that nonsur-
gical periodontal therapy decreases the glomerular filtration
rate (GFR), as assessed by cystatin C levels [90]. A systematic
review assessing the relationship between periodontitis and
CKD concluded that consistent evidence supports a positive
association between the two diseases and the positive effects
of periodontal treatment on GFR [91]. It is noteworthy that the
only RCTstudy performed till date comprised a comparatively
small study population; therefore, further studies are required
to obtain sufficient evidence [92]. However, plausible mechan-
isms linking other systemic diseases such as diabetes and CKD
to ACVD should be taken into account in order to understand
the relationship between ACVD and periodontitis.
3.7. Animal studies
Several animal studies aimed at clarifying the effects of
periodontopathic bacterial infection on atherogenesis have
documented the formation of atheromatous plaque and the
elevation of systemic inflammatory markers in the murine
model [93—95]. Other studies observed the development of
fatty streaks after periodontal infection in rabbits [96] and
atherosclerotic coronary lesions in normocholesterolemic
and hypercholesterolemic pigs [97]. Bacteremia and bacter-
ial invasion have been observed in humans, and this canexplain the mechanisms linking periodontal infection to
atherogenesis. However, the detection of bacteria in blood
or affected tissues has not been a consistent finding. Without
inducing bacteremia, we demonstrated that oral infection
with P. gingivalis enhanced atherogenesis in apolipoprotein E
(ApoE)-mutant mice, notably accompanying an increase in
LDL cholesterol and decrease in HDL cholesterol, with altered
gene expression profiles related to cholesterol transport
[98,99].
There are several points to consider before these findings
can be extrapolated as a link between human periodontitis
and atherosclerosis. First, intravenous inoculation with bac-
teria, rather than the natural route of infection for human
periodontitis (i.e., via oral tissues), was used in some experi-
ments. Although the occurrence of transient bacteremia on
manipulation of the teeth and periodontal tissues is common,
the extent of bacteremia resulting from a dental procedure is
relatively low [<104 colony-forming units (CFUs) of bacteria
per milliliter] [100]. Moreover, there is no information on the
relationship between the severity and extent of disease and
the extent of bacteremia; therefore, the findings observed
after the direct inoculation of bacteria may not represent
those of naturally occurring periodontitis. Second, most
studies used Apo E-deficient mice that phenotypically
develop hyperlipidemia and atherosclerosis. Whether or
not infection can be a trigger for the development of athero-
sclerosis in this model cannot be addressed.
4. Intervention studies
Currently, there are no interventional studies on primary
(first ischemic event) ACVD prevention. There is a single
interventional study in which periodontal therapy was admi-
nistered as an intervention in a secondary cardiac event
prevention model through five coordinated cardiology—den-
tal centers. In this protocol, 30% of the control subjects
received periodontal treatment in addition to standard care.
This pilot study failed to detect any adverse effects of
periodontal scaling and root planning in individuals with
heart disease as compared with a community care group,
which also received some treatment [101]. The management
of control subjects is an issue when designing RCT interven-
tion studies because ethical concerns can be raised in regard
to the long-term withholding of periodontal treatment.
5. Conclusions
In conclusion, the current epidemiological evidence obtained
from acceptable quality-controlled studies indicates the
relationship between periodontitis and ACVD independent
of known confounders. However, the lack of interventional
studies that show the preventive effects of periodontal
treatment on the future incidence of ACVD weakens the
importance of the relationship between the two diseases.
Interventional studies in the Japanese population are
required because the original characteristics of life style,
serum lipid concentrations, and genetic background need to
be taken into account. These studies should be performed in
multiple centers and on a large scale, and they should
evaluate the feasibility of applicable treatments to contri-
bute to public health. This review shows that we lack clinical
60 K. Tabeta et al.markers to monitor the stability of the effects of periodontal
therapy on ACVD.
Plausible evidence has been accumulated, and additional
studies are required not only for better understanding and
confirmation of these findings but also for the development of
a novel and effective treatment or the isolation of effective
markers to monitor the biological relationship between per-
iodontitis and ACVD.
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